Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , June 26, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it is set to join both the broad-market Russell 3000® and small-cap Russell 2000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, according to a preliminary list of additions posted following the close of the U.S. markets on May 19, 2023. "We are pleased to be included in the Russell U.S. Indexes, which stands as a testament to the significant progress we have made across our cell and gene therapy portfolios," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes

SAN DIEGO , June 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, June 15, 2023 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.

Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

SAN DIEGO , May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET. A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023. Details for the presentations are as follows: Oral Presentation: Title: Expression and Activity of Human Factor VIII (hFVIII) Following Single and Repeat Administration of an Integrating Non-viral Gene Therapy in Multiple Mouse Models of Severe Hemophilia A Presenter: Denise Sabatino, Ph.D.

Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis

Six presentations highlight significant advancements across the Company's Gene Therapy platform Preclinical data supports potential of P-OTC-101 to correct severe Ornithine Transcarbamylase Deficiency (OTCD) following a single dose Data presented establishes proof-of-concept for site-specific knock-in of a transgene using Cas-CLOVER™, Poseida's high-precision gene editing technology SAN DIEGO , May 18, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlights its two oral and four poster presentations on the Company's preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023. "We are excited to highlight multiple advancements across our gene therapy programs and platform technologies at ASGCT, which underscore the significant progress our company has made in the past year," said Brent Warner, President, Gene Therapy at Poseida Therapeutics.

Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock

Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.93 per share a year ago.

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates

Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema, Ph.D., as President, Cell Therapy, adding extensive oncology and allogeneic T cell immunotherapy experience to the Company's leadership team SAN DIEGO , May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

SAN DIEGO , May 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that six data presentations, including two oral presentations, highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually on May 16-20, 2023. Oral Presentations: Title: Preclinical Proof-of-Concept: A Novel Hybrid Gene Therapy Approach to Treat Severe Early-Onset Ornithine Transcarbamylase Deficiency Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases I Presentation Time: Thursday, May 18, 2023, 2:30 – 2:45 PM PST Location: Room 403 AB Abstract Number: 127 Title: Cas-CLOVER Technology Enables Precise Gene Editing and Site-Specific Transgene Insertion in Mouse Liver Session Title: Gene Targeting and Gene Correction: Liver Presentation Time: Thursday, May 18, 2023 3:00 – 3:15 PM PST Location: Room 515 AB Abstract Number: 157 Poster Presentations: Title: Demonstration of Human Factor VIII Expression and Activity Following Single and Repeat Dosing of a Non-Viral Integrating Gene Therapy  Session Title: Wednesday Poster Session Session Date/Time: Wednesday, May 17, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 638 Title: Development of a Novel Non-Viral Gene Therapy Platform Session Title: Thursday Poster Session Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 945 Title: Editing of a γ-Globin (HBG1/HBG2) cis-Regulatory Element in Human Hematopoietic Stem and Progenitor Cells Using Cas-CLOVER™ Technology Reactivates Fetal Hemoglobin Session Title: Thursday Poster Session  Session Date/Time: Thursday, May 18, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 1212 Title: Development and Optimization of Novel Super piggyBac®-Based Hybrid Gene Therapy Approach  Session Title: Friday Poster Session  Session Date/Time: Friday, May 19, 2023, 12:00 PM PST Location: West Hall A Abstract & Poster Board Number: 1318 About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.

Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

SAN DIEGO , May 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that it will participate in the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:15pm PT | 6:15pm ET in Las Vegas. A live webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference

Poseida: Allogeneic CAR-T Biotech With Established Partner.

Poseida: Allogeneic CAR-T Biotech With Established Partner

SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Rafael G. Amado, M.D.

Poseida Therapeutics Appoints Rafael G. Amado, M.D.

SAN DIEGO , April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates

Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society for Medical Oncology Immuno-Oncology 2022 Annual Congress (ESMO I-O) Highlighted preclinical data from P-FVIII-101 gene therapy program at the 64th American Society of Hematology Annual Meeting & Exposition (ASH) SAN DIEGO , March 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the fourth quarter and full year ended December 31, 2022.   "For Poseida, 2022 was a year of execution, progress and validation for our proprietary technology and programs in both cell and gene therapy.

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022

SAN DIEGO , March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M.

Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board

Virtual R&D Day featuring key opinion leaders and Poseida's leadership and scientific team members to be held today at 10:00am ET / 7:00am PT SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT. "R&D Day is our annual showcase for the innovative and exciting science we are advancing at Poseida that continues to drive our leadership in the field of cell and gene therapies," said Mark Gergen, Chief Executive Officer of Poseida Therapeutics.

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.

Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference

SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 22, 2023. Poseida's third-annual R&D Day will feature its executive leadership and scientists for a morning of presentations and fireside chats with special guest speakers exploring the future of cell and gene therapy.

Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023

Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatments for Hemophilia A. Poseida is advancing its broad pipeline with its CAR-T portfolio consisting of both autologous and allogeneic/ off-the-shelf products.

Poseida Therapeutics: New Allogeneic Therapies, Leveraging Non-Viral Engineering

Eric Ostertag, M.D., Ph.D., Founder and current Executive Chairman, to retire from the Board of Directors and remain a consultant to the Company SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Eric Ostertag, M.D.

Poseida Therapeutics Announces Board Change

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable

Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why

Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why

Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle for treatment of Hemophilia A across all ages, which could potentially lead to a functional cure SAN DIEGO , Dec. 11, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will present preclinical data from its P-FVIII-101 gene therapy program, partnered with Takeda, at the 2022 American Society of Hematology (ASH) Annual Meeting being held in New Orleans and virtually December 10–13, 2022. The data establish preclinical proof of principle for the treatment of Hemophilia A using P-FVIII-101, a non-viral liver-directed gene therapy utilizing Poseida's Super piggyBac delivery system, which could potentially lead to a functional cure.

News for Poseida Therapeutics Stock (PSTX)